Treatment of hepatitis C virus infection;Therapie der hepatitis C-virus-infektion

Praxis

Volumn 94, Issue 18, 2005, Pages 721-726

  Zeuzem, St ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

HCV genotype; HIV HCV coinfection; Nonresponder; Pegylated interferon; Ribavirin

Indexed keywords

EID: 80051672620     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.94.18.721     Document Type: Review

References (33)

1. Zeuzem S., Roth W.K., Herrmann G.: Virushepatitis C. Z Gastroenterol 33: 117-132, 1995.
2. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., Kilani A., Areias J., Auperin A., Benhamou J.P., Degott C., Erlinger S.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127: 875-881, 1997.
3. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-1432, 1998. (Pubitemid 28510876)
4. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492, 1998. (Pubitemid 28543496)
5. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z., Ling M.H., Albrecht J.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313, 2002. (Pubitemid 34465173)
6. Camma C., Giunta M., Andreone P., Craxi A.: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 34: 593-602, 2001. (Pubitemid 32328518)
7. Poynard T., Regimbeau C., Myers R.P., Thevenot T., Leroy V., Mathurin P., Opolon P., Zarski J.P.: Interferon for acute hepatitis C. Cochrane Database Syst Rev(1): CD000369, 2002.
8. Camma C., Licata A., Craxi A.: Interferon as treatment for acute hepatitis C: a meta-analysis. Hepatology 36 (suppl): 285A, 2002.
9. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G., Dietrich M., Trautwein C., Manns M.P.: Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345: 1452-1457, 2001.
10. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., Schraut W.W., Schirren C.A., Waechtler M., Backmund M., Pape G.R.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125: 80-88, 2003. (Pubitemid 36799109)
11. Hofer H., Watkins-Riedel T., Janata O., Penner E., Holzmann H., Steindl-Munda P., Gangl A., Ferenci P.: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 37: 60-64, 2003. (Pubitemid 36042145)
12. EASL International Consensus Conference on hepatitis C: Consensus statement. J Hepatol 31 (suppl): 3-8, 1999.
13. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology 36 (suppl): S3-S15, 2002.
14. Zeuzem S., Welsch C., Herrmann E.: Pharmacokinetics of peginterferons. Semin Liver Dis 23 (suppl 1): 23-28, 2003. (Pubitemid 37052441)
15. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr, Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
16. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001. (Pubitemid 32913521)
17. Hadziyannis S.J., Sette H. Jr, Morgan T., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H.C., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M., for the PEGASYS" International Study Group: Peginterferon alfa-2a (40 kD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med: im Druck, 2003.
18. Zeuzem S., Hultcrantz R., Bourliere M., Goeser T., Marcellin P., Sanchez-Tapias J., Harvey J., Brass C., Albrecht J.: Peginterferon alfa-2b 1.5mg/kg plus ribavirin 800-1400mg/day for 24 weeks in patients with HCV 2 or 3. Hepatology 38 (suppl): im Druck, 2003.
19. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652, 2003. (Pubitemid 37052151)
20. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B., Hopf U., Zeuzem S.: Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609, 2003. (Pubitemid 36258782)
21. Zeuzem S., Diago M., Gane E., Reddy R., Pockros P., Farci P., Gitlin N., Lamour F., Lardelli P., Shiffman M.: International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin. Hepatology 38 (suppl.): im Druck, 2003.
22. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., De Pamphilis J.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343: 1673-1680, 2000.
23. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S., Trepo C., Shiffman M.L., Zeuzem S., Craxi A., Ling M.H., Albrecht J., for the International Hepatitis Interventional Therapy Group (IHIT): Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339: 1493-1499, 1998. (Pubitemid 28543497)
24. Shiffman M.L.: Retreatment of patients with chronic hepatitis C. Hepatology 36 (suppl 1): S128-S134, 2002.
25. Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., Cargnel A., Mauss S., Dieterich D., Moreno S., Ferrari C., Poynard T., Rockstroh J.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 16: 813-828, 2002. (Pubitemid 34409005)
26. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., Cohard M., Reynes M., Chevallier M., Ducerf C., Baulieux J., Geffner M., Albrecht J.K., Bismuth H., Trepo C.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124: 642-650, 2003. (Pubitemid 36268483)
27. Peginterferon alfa-2a Produkt-Monographie, Nutley 2002.
28. Peginterferon alfa-2b Produkt-Monographie, Kenilworth 2001.
29. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-1672, 2000.
30. Lindsay K.L., Trepo C., Heintges T., Shiffman M.L., Gordon S.C., Hoefs J.C., Schiff E.R., Goodman Z.D., Laughlin M., Yao R., Albrecht J.K., Hepatitis Interventional Therapy Group: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395-403, 2001. (Pubitemid 32702353)
31. Mangia A., Leandro G., Helbling B., Renner E.L., Tabone M., Sidoli L., Caronia S., Foster G.R., Zeuzem S., Berg T., di Marco V., Cino N., Andriulli A.: Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from 6 clinical trials. Hepatology 36 (suppl): 571A, 2002.
32. Berg T., Kronenberger B., Hinrichsen H., Gerlach T., Buggisch P., Herrmann E., Spengler U., Goeser T., Nasser S., Wursthorn K., Pape G.R., Hopf U., Zeuzem S.: Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 37: 1359-1367, 2003. (Pubitemid 36667316)
33. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., Dienstag J., Lee W.M., Mak C., Garaud J.J., Albrecht J.K.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.